Unity Biotechnology racks up $116 mln
Unity Biotechnology Inc, which develops treatments that prevent, halt, or reverse numerous diseases of aging, has raised $116 million in Series B financing. The investors included ARCH Venture Partners, Baillie Gifford, Fidelity Management & Research Company, Partner Fund Management, Venrock, Bezos Expeditions, WuXi PharmaTech and Mayo Clinic Ventures.
28 October 2016•1 min read
